Novo Nordisk will begin a new late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10, according to a entry. The Danish drugmaker last month revealed disappointing ...

Novo Nordisk shares were 9.5% higher after the pharmaceutical giant said an experimental weight-loss shot showed patients ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Alexandra Sowa's new book The Ozempic Revolution is intended to be the "first comprehensive user guide" to GLP-1 drugs like ...

Weight-loss medicines such as Ozempic might raise a person’s likelihood of developing conditions including arthritis.

A serial entrepreneur and a promising drug emerge from failed companies to pursue subsets of obesity patients, with or ...

The phase Ib/IIa study evaluated the safety, tolerability, pharmacokinetics and proof-of-concept of three doses of amycretin in obesity patients ... of action of the drugs. Wegovy contains ...

Indian biopharma company Biocon reported third-quarter revenue on Thursday that fell about 3% when compared with the year-earlier period, which included revenue from its domestic branded formulation ...

Novo Nordisk said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the ...

The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with ...

Novo Nordisk shares rose sharply Friday after the Danish pharmaceutical giant said an experimental weight-loss shot helped patients lose 22% of their body weight in a clinical trial. Shares were 7 ...